RB
Roy D. Baynes (Director) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Travere Therapeutics, Inc. (TVTX). The largest single filing was $2.8M of NTRA (12,780 sh across 8 lots, as filed), executed Nov 19 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
6
0 buys · 6 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.5M
shares × price, as filed
Last traded
Jun 12
Filed Jun 16
Median ADV $454.8M across their filed names
Open performance→Volume by month
Buys $0
Sells $5.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
6 filings
Sector per market data · by filing · past 12 months
Most traded names
TVTXRecent filings
TVTXSALE
Travere Therapeutics, Inc.
View filing →
$225K4,500 sh × $50.00
Exec Jun 12
Filed Jun 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $210K
4,500 sh × $46.65
Exec May 5
Filed May 6 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $431K
9,750 sh × $44.22
Exec May 1
Filed May 4 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $1.4M
32,750 sh across 2 lots
Exec Apr 14
Filed Apr 16 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $330K
10,000 sh × $33.00
Exec Apr 6
Filed Apr 7 · 5:30 PM ET NTRASALE Natera, Inc. View filing → $2.8M
12,780 sh across 8 lots
Exec Nov 19 2025
Filed Nov 21 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $220K
10,000 sh × $22.00
Exec Feb 6 2025
Filed Feb 10 2025 · 5:30 PM ET TVTXSALE Travere Therapeutics, Inc. View filing → $320K
16,000 sh × $20.00
Exec Jan 23 2025
Filed Jan 23 2025 · 5:30 PM ET More filings →